Long-term Impact of NMDAR Encephalitis, Level 3 (SAPIENCE 3)
Status
Conditions
Treatments
Details and patient eligibility
About
NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored.
Currently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients with NMDAR encephalitis
- Age ≥ 18 years old
- Patient affiliated to a social security system
- No opposition from the patient
- Access to an internet connection and a computer
Exclusion criteria
- Patients whithout NMDAR encephalitis
- Patient under guardianship or curatorship
- Patient with neurological disorders pre-existing encephalitis
Trial design
30 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Chloé BUTTARD; Jérôme HONNORAT, Pr
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal